RecruitingPhase 4NCT03975829
Pediatric Long-Term Follow-up and Rollover Study
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- dabrafenib(drug)
- Enrollment
- 165 enrolled
- Eligibility
- 1-99 years · All sexes
- Timeline
- 2019 – 2026
Study locations (19)
- Phoenix Children s Hospital, Phoenix, Arizona, United States
- Childrens National Hospital, Washington D.C., District of Columbia, United States
- Nicklaus Childrens Hospital, Miami, Florida, United States
- Indiana Uni School of Medicine, Indianapolis, Indiana, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
- Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
- St Jude Childrens Research Hospital, Memphis, Tennessee, United States
- Texas Childrens Hospital, Houston, Texas, United States
- Novartis Investigative Site, CABA, Buenos Aires, Argentina
- Novartis Investigative Site, Darlinghurst, New South Wales, Australia
- Novartis Investigative Site, Parkville, Victoria, Australia
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03975829 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco